China News Service, January 7th. On January 6, Yiling Pharmaceutical invested 50 million yuan in funds and materials to the China Red Cross Foundation to initiate the establishment of the "Lianhua Respiratory Health Public Welfare Program" project.

Member of the Party Group and Vice Chairman of the Chinese Red Cross Society, Sun Shuopeng, Executive Vice Chairman of the Chinese Red Cross Foundation, Bei Xiaochao, Vice Chairman and Secretary-General of the Chinese Red Cross Foundation, and Guo Shuanggeng, Consultant of Yiling Pharmaceutical Industry, attended the project launch ceremony.

Yiling Pharmaceutical

  It is understood that Yiling Pharmaceutical plans to distribute Lianhua Qingwen Capsules, Lianhuaqing Cough Tablets, Lianhua Qingwen Blasting Pearls, Lianhuaqing Cough Tablets, Lianhua Qingwen Capsules, Lianhuaqing Cough Tablets, and Lianhua Qingwen Blasting Pearls to areas more severely affected by the epidemic through the implementation of the "Lianhua Breathing Health Charity Program" project. Lianhua's respiratory health products, including blast pearl masks and health packs, support the local epidemic prevention and control work.

In the context of the normalization of epidemic prevention and control, the prevention and treatment of cold and flu diseases of special groups, the skill training of pharmacy personnel, and popular science education on respiratory diseases of the general public are carried out.

  Lianhua Qingwen Capsules (granules) is a patented innovative Chinese medicine, the National Essential Drug List and the National Medical Insurance List (Class A) of Ling Pharmaceutical. It is mainly used for the treatment of colds, flu, new coronary pneumonia and other diseases.

Since the outbreak of the new crown pneumonia epidemic, Lianhua Qingwen Capsules (granules) have been jointly issued by the National Health Commission and the State Administration of Traditional Chinese Medicine in the "New Coronavirus Pneumonia Diagnosis and Treatment Plan" (trial version 4/5/6/7/8) ) And recommendations for the diagnosis and treatment of new coronary pneumonia in more than 20 provinces and cities.

In April 2020, the National Medical Products Administration approved Lianhua Qingwen Capsules (granules) to add new indications of "New Coronavirus Pneumonia Light and Common" on the basis of the original indications.

  At present, Lianhua Qingwen Capsules have been approved for marketing in more than 20 countries and regions including Canada, Russia, the Philippines, Kuwait, Kyrgyzstan, and registered in dozens of countries around the world.

In the 17 years since Lianhua Qingwen was listed, it has received more than 20 national-level treatment recommendations during major viral public health events such as influenza A, influenza B, avian influenza and new coronary pneumonia.

  Lianhua Qingke Tablets is a Chinese medicine patent newly approved by Ling Pharmaceutical in May 2020. It is a national medical insurance product. It has the effects of dispelling the lungs and relieving heat, reducing phlegm and relieving cough.

It can not only dilute sputum and promote sputum discharge, but after sputum discharge, it can reduce the blockage of trachea and bronchus and unblock the respiratory tract.

It can also reduce inflammation, thereby reducing airway hyperresponsiveness caused by airway inflammation.

In addition, Lianhua Qingke Tablets have broad-spectrum antibacterial and antiviral effects, and have inhibitory effects on Staphylococcus aureus, A hemolytic streptococcus, B hemolytic streptococcus, and pneumococcus.

  At the same time, the "Clinical Efficacy Observation of Lianhua Qing Cough Treating Mild and Common New Coronavirus Pneumonia" jointly carried out by 6 hospitals including Hebei Chest Hospital showed that the addition of Lianhua Qing cough on the basis of conventional treatment can significantly improve the new crown Cough and sputum symptoms in patients with pneumonia, promote the improvement of cough and sputum symptoms, shorten the duration of cough and sputum symptoms, increase the disappearance rate of cough and sputum symptoms, reduce lung disease, improve respiratory function, and prevent fever, fatigue, Symptoms of dry throat and sore throat also showed a good improvement trend.

During the new crown pneumonia epidemic last year, Lianhua Qingke Tablets passed the emergency record of the Hebei Provincial Drug Administration and recommended by the Hebei Provincial Administration of Traditional Chinese Medicine to be used in the medical treatment of new crown pneumonia.

  As one of the top 500 listed companies in China by market capitalization, the top 20 listed pharmaceutical companies in China, and the top 10 Chinese medicine companies, Yiling Pharmaceuticals actively assumes corporate social responsibility.

During the 2020 new crown pneumonia epidemic, Yiling Pharmaceutical has donated a total of more than 20 million yuan worth of epidemic prevention materials such as Lianhua Qingwen Capsules to the Chinese Red Cross for epidemic prevention and control.